Paper39100673
A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.
Guselnikov SV and 22 others. Front Immunol, 2024. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants. Papers, record 39100673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39100673
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| SARS-CoV-2 | Major topic |
| COVID-19 | Major topic |
| Mice, Transgenic | Major topic |
| Angiotensin-Converting Enzyme 2 | Major topic |
| Antibodies, Viral | Major topic |
| Antibodies, Monoclonal | Major topic |
| Antibodies, Neutralizing | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Spike Glycoprotein, Coronavirus | |
| Pandemics | |
| Broadly Neutralizing Antibodies | |
| Disease Models, Animal |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,990,214 | Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. | Science | 2022 | https://conductscience.org/library/papers/34990214 | PubMed |
| 2 | 32,454,512 | A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. | Nature | 2020 | https://conductscience.org/library/papers/32454512 | PubMed |
| 3 | 32,422,645 | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. | Nature | 2020 | https://conductscience.org/library/papers/32422645 | PubMed |
| 4 | 36,319,593 | Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines. | J Med Virol | 2023 | https://conductscience.org/library/papers/36319593 | PubMed |
| 5 | 36,493,787 | Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. | Cell Rep | 2022 | https://conductscience.org/library/papers/36493787 | PubMed |
| 6 | 34,261,126 | SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. | Nature | 2021 | https://conductscience.org/library/papers/34261126 | PubMed |
| 7 | 33,436,577 | A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. | Nat Commun | 2021 | https://conductscience.org/library/papers/33436577 | PubMed |
| 8 | 17,996,249 | Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. | J Immunol Methods | 2008 | https://conductscience.org/library/papers/17996249 | PubMed |
| 9 | 38,109,919 | Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. | Lancet Infect Dis | 2024 | https://conductscience.org/library/papers/38109919 | PubMed |
| 10 | 33,820,835 | The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. | Sci Transl Med | 2021 | https://conductscience.org/library/papers/33820835 | PubMed |
| 11 | 37,219,999 | Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination. | Cell Rep | 2023 | https://conductscience.org/library/papers/37219999 | PubMed |
| 12 | 32,805,021 | CoV-AbDab: the coronavirus antibody database. | Bioinformatics | 2021 | https://conductscience.org/library/papers/32805021 | PubMed |
| 13 | 38,302,341 | SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences. | Trends Immunol | 2024 | https://conductscience.org/library/papers/38302341 | PubMed |
| 14 | 32,540,901 | Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. | Science | 2020 | https://conductscience.org/library/papers/32540901 | PubMed |
| 15 | 15,035,025 | SARS--beginning to understand a new virus. | Nat Rev Microbiol | 2003 | https://conductscience.org/library/papers/15035025 | PubMed |
| 16 | 37,845,314 | SARS-CoV-2 evolution in the Omicron era. | Nat Microbiol | 2023 | https://conductscience.org/library/papers/37845314 | PubMed |
| 17 | 35,568,025 | LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. | Cell Rep | 2022 | https://conductscience.org/library/papers/35568025 | PubMed |
| 18 | 38,400,113 | Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/38400113 | PubMed |
| 19 | 35,081,335 | SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. | Cell | 2022 | https://conductscience.org/library/papers/35081335 | PubMed |
| 20 | 36,580,913 | Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. | Cell | 2023 | https://conductscience.org/library/papers/36580913 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41,874,023 | Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/41874023 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| H19-ICR | 105,259,599 | PubTator's text mining | https://conductscience.org/library/genes/105259599 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39100673
GET https://conductscience.org/api/papers/v1/39100673/authors?page=2